In Norway, a place in a state care home for the elderly costs $100,000 a year per person. Japan has an old legend about obasute: the practice of carrying the elderly into the mountains to die once they became a burden. A legend. But modern Japan records around 80,000 cases of "lonely death" (kodokushi) every year: someone dies at home and goes unnoticed for weeks. That's not cruelty. It's the consequence of intergenerational ties wearing down to nothing.
The opposite pole is the Caucasus. Abkhazia, Georgia, and the mountain regions of Azerbaijan hold some of the world's highest concentrations of centenarians. The secret, it turns out, is embarrassingly simple: intact social ties, contact between generations, physical work well into old age, and, above all, a sense of being needed. Here, an elder is an asset, not a burden.
Gulf states understand this at government level too. The Hevolution Foundation (Saudi Arabia) invests $1 billion a year in biological ageing research. Not philanthropy. Strategy. The region is betting that its population will live to see the next century in sound mind and body.
2026 science is giving these efforts a molecular foundation. In May, Nature published a study covering more than 11,000 transcriptomes across 25 tissues from mice, rats, macaques and humans, identifying conserved ageing signatures that operate the same way across all mammals. In July, the same journal reported 29 genetic loci, known as VITA, that govern mortality within specific age windows: the genes that kill at 60 differ from the ones that kill at 75. Ageing isn't a single process. It's a series of programmes, each with its own switch.
One of the most promising avenues is the fight against senescent cells: biological rubbish, cells that have stopped dividing but haven't died. They accumulate and poison surrounding tissue with inflammation, and that build-up is ageing at the cellular level. A vaccine-based approach to clearing them is unconventional, which is exactly why the market finds it interesting. That same market has already put $4.2 billion in private capital into longevity biotech over three years.
"In cultures where an elder is an asset, not a burden, demographic crises are solved differently. The family as an institution is the oldest form of social insurance we have, and we dismantled it without inventing anything better," said Ibrahim Diane, VOSTOK ONE.
The opposite pole is the Caucasus. Abkhazia, Georgia, and the mountain regions of Azerbaijan hold some of the world's highest concentrations of centenarians. The secret, it turns out, is embarrassingly simple: intact social ties, contact between generations, physical work well into old age, and, above all, a sense of being needed. Here, an elder is an asset, not a burden.
Gulf states understand this at government level too. The Hevolution Foundation (Saudi Arabia) invests $1 billion a year in biological ageing research. Not philanthropy. Strategy. The region is betting that its population will live to see the next century in sound mind and body.
2026 science is giving these efforts a molecular foundation. In May, Nature published a study covering more than 11,000 transcriptomes across 25 tissues from mice, rats, macaques and humans, identifying conserved ageing signatures that operate the same way across all mammals. In July, the same journal reported 29 genetic loci, known as VITA, that govern mortality within specific age windows: the genes that kill at 60 differ from the ones that kill at 75. Ageing isn't a single process. It's a series of programmes, each with its own switch.
One of the most promising avenues is the fight against senescent cells: biological rubbish, cells that have stopped dividing but haven't died. They accumulate and poison surrounding tissue with inflammation, and that build-up is ageing at the cellular level. A vaccine-based approach to clearing them is unconventional, which is exactly why the market finds it interesting. That same market has already put $4.2 billion in private capital into longevity biotech over three years.
"In cultures where an elder is an asset, not a burden, demographic crises are solved differently. The family as an institution is the oldest form of social insurance we have, and we dismantled it without inventing anything better," said Ibrahim Diane, VOSTOK ONE.
Germany is moving the other way: a pension shortfall, a labour shortage, and labour migration used as a temporary patch over a structural wound. Japan is its own case entirely: the country with the world's longest-lived population also holds the record for overwork. “Karoshi” (death from overwork) is a Japanese term with no exact translation elsewhere, because nowhere else has quite got there yet.
Africa stands apart. Fewer than three doctors per 10,000 people, against more than 36 in Europe. A predator doesn't chase the strongest prey. It goes where the defences are weakest: in Europe, attacks have moved from servers to cars, and then to IoT devices, as each frontier hardened in turn. Senegal has weathered attacks on its tax authority, interior ministry and treasury within a single year. Africa's low digitisation isn't a shield against cyberattacks, only a matter of time. But the real threat here isn't that. It's the absence of a healthcare system at all. Up to 30% of medicines on the continent are counterfeit. A cancer patient gets paracetamol where they need biologic therapy. That's not a logistics problem. It's a political one.
Africa stands apart. Fewer than three doctors per 10,000 people, against more than 36 in Europe. A predator doesn't chase the strongest prey. It goes where the defences are weakest: in Europe, attacks have moved from servers to cars, and then to IoT devices, as each frontier hardened in turn. Senegal has weathered attacks on its tax authority, interior ministry and treasury within a single year. Africa's low digitisation isn't a shield against cyberattacks, only a matter of time. But the real threat here isn't that. It's the absence of a healthcare system at all. Up to 30% of medicines on the continent are counterfeit. A cancer patient gets paracetamol where they need biologic therapy. That's not a logistics problem. It's a political one.